Business Wire

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Share

Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the first publication of preclinical and clinical Phase I/II data on TOTUM•63 in three peer-reviewed international scientific journals: the American Journal of Physiology-Endocrinology and Metabolism, the International Journal of Obesity and Nutrients. These papers bring together a first set of results from the development of this active substance for the reduction of the risk of type 2 diabetes. They represent a first and comprehensive elucidation of mechanisms of action, to prepare for further scientific communications as part of a strategy of TOTUM•63, developed in collaboration with Nestlé Health Science as part of the global strategic partnership. This plan includes the publication of all TOTUM•63 preclinical and clinical results to accompany subsequent marketing of this active substance.

Pascal SIRVENT, Chief Scientific Officer, member of the Valbiotis Board of Directors, comments: ‘These three publications by leading journals constitute a major scientific recognition of our R&D work on TOTUM•63 for the prevention of type 2 diabetes. They represent a very powerful endorsement of the TOTUM•63 results, already presented at international congresses, on carbohydrate homeostasis and weight, on the pleiotropic mode of action of this active substance on several tissues, and on its safety of use. New preclinical data on the benefit of TOTUM•63 in combination with physical activity has also been published. This first publishing success kicks off our scientific promotion strategy for this program, which is being carried out alongside our partner Nestlé Health Science and will lead to the comprehensive publication of the results obtained with TOTUM•63. This strategy reflects our high scientific standards. But above all, it is a decisive factor for the successful marketing of TOTUM•63 throughout the world.’

Hans-Juergen WOERLE, Chief scientific and chief medical officer at Nestlé Health Science, states: ‘Comprehensive scientific publications for TOTUM•63 ensure high scientific validity of the quality of results for this active substance. This is instrumental for a health product, where often times a comprehensive understanding of mechanisms are lacking, and will pave the way for anticipated use of TOTUM•63 in prediabetes and blood glucose disorders. We are delighted with these first publications, working alongside the Valbiotis teams and its highly reputable academic partners.’

First three publications in leading international peer-reviewed journals

The three papers have been accepted and published in the following three journals:

  • The American Journal of Physiology, published since 1898 by the American Physiology Society, the main American scientific society dedicated to physiology and all its disciplines. 5-year Impact Factor: 4.209.
  • The International Journal of Obesity, published by the Nature group, one of the world's most respected scientific publishers. It promotes the study of obesity through a multidisciplinary approach. 5-year Impact Factor: 5.336.
  • Nutrients, a journal of the MDPI Group, a pioneer in online scientific publishing. It is supportedby a consortium of several national and international learned societies in the field of nutrition. 5-year Impact Factor: 5.089.

The research work on which these publications are based was carried out by the Valbiotis R&D platform and through close collaboration between the Company and its French and international academic partners. The University of Clermont Auvergne, the Clermont Auvergne Clinical Investigation Center (Centre d’investigation clinique Clermont Auvergne), La Rochelle University, Claude Bernard University in Lyon, INRA, INSERM, CNRS, Vanderbilt University in Nashville (USA) and Leiden University (Netherlands) are among the co-authors.

Citations:

- Chavanelle V et al., Effects of TOTUM•63 on glucose homeostasis and post‐prandial glycemia: a translational study, American journal of Physiology – Endocrinology and metabolism, 2021.
journals.physiology.org/doi/abs/10.1152/ajpendo.00629.2020

- Van der Zandea H. et al., Effects of a novel polyphenol-rich plant extract on body composition, inflammation, insulin sensitivity and glucose homeostasis in obese mice, International Journal of Obesity, 2021.
www.nature.com/articles/s41366-021-00870-x

- Dupuit M. et al., The TOTUM•63 Supplement and High-Intensity Interval Training Combination Limits Weight Gain, Improves Glycemic Control, and Influences the Composition of Gut Mucosa-Associated Bacteria in Rats on a High Fat Diet, Nutrients, 2021.
www.mdpi.com/2072-6643/13/5/1569

About TOTUM•63
TOTUM•63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes.
TOTUM•63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM•63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM•63 significantly reduced body weight and waist circumference.
TOTUM•63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia, China, Japan, Mexico, Indonesia, Israel, South Africa, New-Zealand and national phases are underway in more than 10 countries including Brazil and Australia. The ability to produce TOTUM•63 industrially, in compliance to North American and European standards, has been validated. TOTUM•63 already has marketing authorizations related to its status in Europe.
In 2020, Valbiotis has signed a global and long-term partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63. This unique partnership in the field of Nutrition Health plans that TOTUM•63 will be put on the market by Nestlé Health Science at a global level, possibly before obtaining a health claim, depending on the areas. It will also provide funding for the latest development stages of TOTUM•63.

About Valbiotis
VALBIOTIS is a Research & Development company committed to scientific innovation preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com.

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
media@valbiotis.com

Financial communication / Actifin
Stéphane Ruiz
+33 1 56 88 11 14
sruiz@actifin.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Walton Enters the Single-Family Build-to-Rent Market Using its 81,000 Acre Land Portfolio Throughout the U.S.23.6.2021 16:18:00 EEST | Press release

Walton Global Holdings has launched a build-to-rent (BTR) line of business that will leverage its more than 81,000 acres of land assets throughout the U.S. to create near-term opportunities for single-family home rental developments. Walton is a global real estate investment and land asset management company with US$3.4 billion under management making the company one of the largest pure-play residential landowners in North America. The launch of Walton’s BTR business provides the company with an immediate competitive advantage during a time when established land parcels are hard to come by for many organizations in this market. Walton’s core products have been pre-development land and land development for more than 42 years. Through its core business, Walton specializes in land acquisition to zoning and entitlements partnering with top national homebuilders throughout the U.S. Walton has already identified 17 near-term opportunities and is in advanced negotiations with a select group o

A European Leader in Retail for Automotive Launches Its Data Exchange Platform Powered by Dawex23.6.2021 16:00:00 EEST | Press release

Dawex, the leading data exchange and data marketplace technology company, today announced a European leader in retail for automotive has chosen Dawex technology to deploy its Data Exchange Platform to distribute, exchange and commercialize data products securely, in compliance with regulations. Relying on Dawex technology, the Data Exchange facilitates access to data products, accelerates data circulation and monetization, and orchestrates a data ecosystem. This data hub enables the entire sector to propose new services, improve productivity and efficiency, mitigate risk, and generate new revenue streams. Our customer’s Data Marketplace empowers participating organizations to build strong data partnerships where data providers and data acquirers benefit from the appropriate governance models to ensure participants remain in full control over the data they share, with whom they share it with, and for which usage. Dawex Data Exchange technology brings the technical, contractual, financia

Sevan Named Great Place to Work® 8 Years in a Row23.6.2021 16:00:00 EEST | Press release

For the eighth year in a row, Sevan Multi-Site Solutions, Inc. (Sevan), a leader in delivering innovative design, program management, construction services and data analytics to organizations with multiple sites, has been recognized as a Great Place to Work®. “Sevan’s culture focuses on people first, which is evident in our renewed status as a Great Place to Work®,” said Jim Evans, President and CEO of Sevan. “Our people are the heart and soul of our business, and their passion for excellence is the reason for our continued success with our clients.” This year a record 92% of Sevan’s team members participated in the Great Place to Work® survey, and over 90% surveyed say Sevan is a great place to work. These team members also say Sevan’s management is honest and ethical, the company contributes positively to the community and that Sevan is an organization they are proud to work for. “Certified companies put employees first,” said Michael C. Bush, CEO at Great Place to Work. “Thriving em

IDEMIA Brings Boarding Security to Los Angeles International Airport (LAX)23.6.2021 16:00:00 EEST | Press release

IDEMIA is facilitating a facial recognition system to help U.S. Customs and Border Protection (CBP) increase air passengers’ security and border control at Los Angeles International Airport (LAX), one of the busiest airports in the world. The technology has been deployed in LAX’s new West Gates at Tom Bradley International Terminal and is a one-stop safety solution for passengers, airlines, and airports alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005420/en/ (Photo: Business Wire) The deployment is part of a contract awarded by Los Angeles World Airports (LAWA) to EASIER, a leader in e-gate technology. In alignment with protection measures defined by the U.S. Congress, passengers will now get to experience a faster, more accurate, and touchless boarding experience. LAX is just one of multiple airports where IDEMIA’s facial recognition technology is deployed in conjunction with CBP and an example of the long-te

Leading Liver Disease Researchers Present at EASL International Liver Congress™ 2021, Demonstrate Prognostic Value of Echosens’ FibroScan-based Agile Scores for Patients with Liver Disease23.6.2021 15:53:00 EEST | Press release

Echosens, a high-technology company offering the FibroScan family of products, today announces that distinguished researchers will present studies supporting the value of FibroScan at EASL’s International Liver Congress, June 23-26, 2021. An area of focus will be FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. “Agile scores were built on a large and global pool of patient data and have been externally validated on two large cohorts of patients—one from France and one from the United States—to achieve this exceptional level of score development,” says Dominique Legros, Group CEO, Echosens. “These novel, noninvasive scores reduce the number of false positive cases compared to liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE™) alone, accurately predict liver complications and, in coming years, will identify patients eligible for pharmaceutical treatments.” Currently a

Sherlock Biosciences’ 221b Foundation Enables Global Access to COVID-19 Diagnostics with Up To 10 Million Tests Per Month23.6.2021 15:30:00 EEST | Press release

The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies, Cooper International, LogicInk, Rokline, United PPE and binx health, The 221b Foundation has enabled manufacturing and global distribution in the U.S., United Arab Emirates, India and Singapore, and is in discussions to expand beyond these geographies to increase access for vital diagnostic solutions around the world. The 221b Foundation was founded to aid in the fight against the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from third-party sales of SHERLOCK CRISPR COVID-19 products have

Tarjousasiakirja koskien Adapteo Oyj:n hallituksen suosittelemaa julkista käteisostotarjousta Adapteo Oyj:n osakkeenomistajille on julkaistu23.6.2021 15:00:00 EEST | Tiedote

Tämä tiedote ei ole suoraan tai välillisesti tehty tarjous Australiassa, Kanadassa, Hongkongissa, Japanissa, Uudessa-Seelannissa tai Etelä-Afrikassa, tai millään muulla alueella, jossa tarjous olisi sovellettavan lain vastainen. Osakkeenomistajat, jotka eivät ole Ruotsissa tai Suomessa ja jotka haluavat hyväksyä Ostotarjouksen (kuten määritelty alla) tulee tehdä omat selvityksensä soveltuvasta lainsäädännöstä ja mahdollisista veroseuraamuksista. Osakkeenomistajia kehotetaan tutustumaan ostotarjoukseen kohdistuviin rajoituksiin kohdassa ”Tärkeää tietoa” tämän tiedotteen lopussa sekä tarjousasiakirjassa. Yhdysvalloissa olevia osakkeenomistajia kehotetaan myös katsomaan osio ”Tietoja osakkeenomistajille Yhdysvalloissa” tämän tiedotteen lopussa ja tarjousasiakirjassa. LEHDISTÖTIEDOTE 23.6.2021 Palace Bidco Oy (“WSIP Bidco”), joka on West Street Global Infrastructure Partners IV, L.P.:n (“WSIP”) lukuun perustettu ja sen välillisesti kokonaan omistama yksityinen osakeyhtiö, julkisti 17.5.202

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom